A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries

Launched by VERTEX PHARMACEUTICALS INCORPORATED · Mar 19, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new medication called Suzetrigine (SUZ) to see how well it works and how safe it is for managing acute pain after certain types of surgeries. Specifically, the study will focus on patients who are having laparoscopic surgeries (which are minimally invasive surgeries done through small incisions) or arthroscopic orthopedic surgeries (which involve joints). The goal is to find out if SUZ can help manage pain for at least 72 hours after these procedures, which typically would require stronger pain medications like opioids.

To participate in this study, you need to be between 65 and 74 years old and have a body mass index (BMI) between 18.0 and 40.0. You should be scheduled for one of the specified surgeries. If you have previously participated in a study involving Suzetrigine or have taken a medication called Journavx, you won't be eligible. If you join the trial, you'll receive the medication and be monitored to assess how well it's working and whether you experience any side effects. This study is still in the planning stages and has not started recruiting participants yet.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m\^2)
• • Scheduled to undergo a procedure that is in one of the following categories that would typically be treated with opioid therapy for at least 72 hours postoperatively such as
• • Laparoscopic intraperitoneal or retroperitoneal procedure
• • Arthroscopic orthopedic procedure
• Key Exclusion Criteria:
• • -Participated in previous study with Suzetrigine or received Journavx
• • Other protocol defined Inclusion/Exclusion criteria will apply.